ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Prospective Study |
Article Title |
Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome
|
Manuscript Source |
Invited Manuscript |
All Author List |
Konstantinos Kargiotis, Vasilios G Athyros, Olga Giouleme, Niki Katsiki, Evangelia Katsiki, Panagiotis Anagnostis, Chrysoula Boutari, Michael Doumas, Asterios Karagiannis and Dimitri P Mikhailidis |
Funding Agency and Grant Number |
|
Corresponding Author |
Dimitri P Mikhailidis, MD, FFPM, FRCP, FRCPath Academic Head, Department of Clinical Biochemistry (Vascular Disease Prevention Clinic), Royal Free Hospital Campus, University College London Medical School, University College London, Pond Street, NW3 2QG London, United Kingdom. mikhailidis@aol.com
|
Key Words |
Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Metabolic syndrome; Dyslipidaemia; Rosuvastatin; Fasting blood glucose; Serum uric acid |
Core Tip |
We treated 20 patients with metabolic syndrome (MetS) and biopsy proven non-alcoholic steatohepatitis (NASH) with rosuvastatin monotherapy for one year. Repeat liver biopsy and ultrasonography showed complete resolution of NASH in 19 patients, and normalization of liver enzymes, lipid profile and blood glucose; no patient had MetS at the end of the study. These findings suggest that rosuvastatin monotherapy could ameliorate biopsy proven NASH and resolve MetS within 12 mo. These effects and the reduction of fasting plasma glucose and serum uric acid levels, if confirmed by larger studies, may reduce the risk of vascular and liver morbidity and mortality in NASH patients. |
Publish Date |
2015-07-08 12:01 |
Citation |
Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, Boutari C, Doumas M, Karagiannis A, Mikhailidis DP. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21(25): 7860-7868 |
URL |
http://www.wjgnet.com/1007-9327/full/v21/i25/7860.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v21.i25.7860 |